Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine

This study has been completed.
Sponsor:
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by:
Janssen-Ortho LLC
ClinicalTrials.gov Identifier:
NCT00210496
First received: September 13, 2005
Last updated: May 16, 2011
Last verified: April 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2007
  Estimated Primary Completion Date: No date given